Viromed Enters European Cosmetics Market with Exclusive ViroCAP® Deal

Viromed Medical AG has signed an exclusive agreement with Landsberg First Class Aesthetic to commercialize the ViroCAP® My Plasma device for cosmetic and aesthetic uses in Europe. This marks Viromed's entry into the European cosmetics market, enabled by Landsberg's extensive B2B network. The partnership aims to introduce 5,000 devices over three years, enhancing long-term revenue through related sales.

ViroCAP® uses cold plasma technology to inactivate viruses and bacteria, promoting sterility and accelerating healing in aesthetic treatments. Landsberg's clientele includes aesthetic doctors and high-class institutes, demanding high-quality products and services.

Landsberg will market ViroCAP® under its brand, presenting it as the sole unique device in its category, thereby promising a step forward in aesthetic and clinical skincare innovation.